Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Colombo, G.
Right arrow Articles by Gessa, G. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Colombo, G.
Right arrow Articles by Gessa, G. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Alcohol and Alcoholism Vol. 37, No. 5, pp. 477, 2002
© 2002 Medical Council on Alcohol

PROCEEDINGS OF A SYMPOSIUM ENTITLED: 'GABAB RECEPTORS: A TARGET OF NEW TREATMENTS FOR ALCOHOLISM AND DRUG ABUSE'

INTRODUCTION

Giancarlo Colombo and Gian Luigi Gessa

Department of Neuroscience ‘Bernard B. Brodie’, University of Cagliari, Cittadella Universitaria, S. S. 554, Monserrato (CA) I-09042, Italy

The first 10% of the full text of this article appears below.

In recent years, accumulating lines of evidence have suggested that the {gamma}-aminobutyric acid (GABA)B receptor agonists, and particularly baclofen, may reduce the reinforcing properties of drugs of dependence (specifically cocaine, heroin, nicotine and alcohol), limiting their self-administration in laboratory animals and, in the few clinical studies conducted to date, their use by human addicts. The interest in this promising pharmacotherapeutic strategy in the addiction field led us . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?